I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Ticlopidine hydrochloride is a selective P2Y12 receptor antagonist. It inhibits ADP-induced platelet aggregation and displays antithrombotic activity following oral administration in vivo.
B.Bergamasco; P.Benna; A.Carolei; M.Rasura; G.Rudelli; C.Fieschi. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study. Functional Neurology. 1997, 12,(1), 33-43.
J.Shah, PhD; A.Fratis, MA; D.Ellis, MD, PhD; S.Murakami, BS; P.Teitelbaum , PhD. Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. The Journal of Clinical Pharmacology. 1990, 30,(8), 733-736.
Hazard Statements: H302
Harmful if swallowed.
Precautionary Statements: P264-P270-P301+P312a-P330-P501a
Wash thoroughly after handling. Do not eat, drink or smoke when using this product. IF SWALLOWED: Rinse mouth. Dispose of contents/container in accordance with local/regional/national/international regulations.